Inocras closed an oversubscribed $31 million Series B-3 round to expand its U.S. sequencing, analytics, laboratory, and commercial infrastructure.
- Amount
- $31M
- Stage
- Series B
- Announced
- 3 August 2026
- Investors
- NDS Corporation, Aimed Bio Inc., IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, Shinhan Securities
- Use of funds
- Proceeds will fund the U.S. expansion of Inocras's CLIA/CAP-certified whole-genome sequencing and automated analytics infrastructure.
- Total raised
- $100M to date
- Checked
- Amount and date matched across 2 press sources